Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidance On Regulating AI As A Medical Device Not Top 2023 Priority For FDA

Industry Attorney Offers His Perspective On Why It Should Be

Executive Summary

The US FDA’s Center for Devices and Radiological Health has posted the guidance documents it plans to focus on in fiscal year 2023, and guidance on regulating AI as a medical device is not first up.

You may also be interested in...



What A Difference A Year Makes; AI Makes The A-List

The US FDA’s Center for Devices and Radiological Health has announced the guidance documents it plans to focus on in fiscal year 2024, and this time, AI devices make the cut.

Additional User Fee Funding Will Boost Global Harmonization, Says FDA’s Torres

Recently passed legislation that includes higher medical device user fees will allow the US FDA to put more resources into establishing global harmonization standards with international partners.

Software At The Speed Of Trust: US FDA Launches Pilot To Expedite Digital Health Products

Nine companies are asked to volunteer for a pilot program that could lead to a new pathway for sponsors of digital health products. Under the plan, the agency would allow firms to market a product with fewer if any pre-market review requirements based on trust developed in the company's software design and testing. If the project works out, FDA digital health leader Bakul Patel tells Medtech Insight, the agency hopes it will attract more non-traditional medical device firms that specialize in software development.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel